BRCA1 and breast cancer: Experiments revealed that CDDO-Im treatment of non-malignant breast epithelial cells and BRCA1 wild type cell lines does not affect ROS generation, demonstrating unique impact on BRCA1-mutated BC cells, in which CDDO-Im stimulates ROS and, consequently, DNA damage.